Table 2.
Additional non-susceptibility (R + I) against | |||
---|---|---|---|
Non-susceptibility (R + I) against | Meropenem | Imipenem | Ertapenem |
Meropenem (n = 634) | – | 501/619 (80.9%) | 299/314 (95.2%) |
Imipenem (n = 569) | 501/562 (89.1%) | – | 252/272 (92.6%) |
Ertapenem (n = 596) | 252/591 (42.6%) | 299/590 (50.7%) | – |
R resistant, I intermediate